In this study, we used A-485 as a strategy to assess the relevance of p300/CBP therapeutic inhibition in the NSCLC setting and to decipher how A-485 affects p300/CBP-dependent cellular death pathways. The gene discussed is CREBBP; the disease is non-small cell lung carcinoma.